DrugCite
Search

PERMIXON

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Permixon Adverse Events Reported to the FDA Over Time

How are Permixon adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Permixon, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Permixon is flagged as the suspect drug causing the adverse event.

Most Common Permixon Adverse Events Reported to the FDA

What are the most common Permixon adverse events reported to the FDA?

Cerebral Haematoma
14 (5.71%)
Eczema
14 (5.71%)
General Physical Health Deteriorati...
12 (4.9%)
Renal Failure
10 (4.08%)
Cerebral Haemorrhage
8 (3.27%)
Rash Maculo-papular
8 (3.27%)
Erythema
7 (2.86%)
Hepatitis
6 (2.45%)
Lung Disorder
6 (2.45%)
Mydriasis
6 (2.45%)
Pupils Unequal
6 (2.45%)
Show More Show More
Altered State Of Consciousness
5 (2.04%)
Cholestasis
5 (2.04%)
Hypercalcaemia
5 (2.04%)
Night Sweats
5 (2.04%)
Coagulopathy
4 (1.63%)
Hyperhidrosis
4 (1.63%)
Incision Site Haemorrhage
4 (1.63%)
Interstitial Lung Disease
4 (1.63%)
Pitting Oedema
4 (1.63%)
Pulmonary Fibrosis
4 (1.63%)
Vertigo
4 (1.63%)
Blood Creatinine Increased
3 (1.22%)
Cardiac Arrest
3 (1.22%)
Eosinophilia
3 (1.22%)
Hyponatraemia
3 (1.22%)
Multiple Drug Overdose Intentional
3 (1.22%)
Nausea
3 (1.22%)
Pancytopenia
3 (1.22%)
Bleeding Time Prolonged
2 (.82%)
Blood Urea Increased
2 (.82%)
Deep Brain Stimulation
2 (.82%)
Dermatitis Bullous
2 (.82%)
Diarrhoea
2 (.82%)
Dizziness
2 (.82%)
Drug Eruption
2 (.82%)
Drug Rash With Eosinophilia And Sys...
2 (.82%)
Haemoglobin Decreased
2 (.82%)
Headache
2 (.82%)
Hepatitis Cholestatic
2 (.82%)
Hepatitis Fulminant
2 (.82%)
Hyperkalaemia
2 (.82%)
Neuropathy Peripheral
2 (.82%)
Oedema Peripheral
2 (.82%)
Prostatic Specific Antigen Increase...
2 (.82%)
Purpura
2 (.82%)
Rash Pustular
2 (.82%)
Skin Necrosis
2 (.82%)
Tremor
2 (.82%)
Vomiting
2 (.82%)
Acne
1 (.41%)
Balance Disorder
1 (.41%)
Bladder Disorder
1 (.41%)
Blood Creatine Increased
1 (.41%)
Bronchial Disorder
1 (.41%)
C-reactive Protein Increased
1 (.41%)
Death
1 (.41%)
Delayed Recovery From Anaesthesia
1 (.41%)
Dermatitis
1 (.41%)
Drug Resistance
1 (.41%)
Dysaesthesia
1 (.41%)
Fall
1 (.41%)
Febrile Bone Marrow Aplasia
1 (.41%)
Gait Disturbance
1 (.41%)
Glycosylated Haemoglobin Increased
1 (.41%)
Haematoma
1 (.41%)
Haemolytic Anaemia
1 (.41%)
Hepatic Steatosis
1 (.41%)
Hypersensitivity
1 (.41%)
Hypoaesthesia
1 (.41%)
Hypotension
1 (.41%)
Iatrogenic Injury
1 (.41%)
Intentional Overdose
1 (.41%)
Liver Disorder
1 (.41%)
Motor Dysfunction
1 (.41%)
Mycosis Fungoides
1 (.41%)
Orthostatic Hypotension
1 (.41%)
Overdose
1 (.41%)
Pancreatitis Necrotising
1 (.41%)
Paraesthesia
1 (.41%)
Peritoneal Effusion
1 (.41%)
Post Procedural Complication
1 (.41%)
Post Procedural Haemorrhage
1 (.41%)
Pseudolymphoma
1 (.41%)
Respiratory Failure
1 (.41%)
Somnolence
1 (.41%)
Toxic Skin Eruption
1 (.41%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Permixon, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Permixon is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Permixon

What are the most common Permixon adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Permixon, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Permixon is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Permixon According to Those Reporting Adverse Events

Why are people taking Permixon, according to those reporting adverse events to the FDA?

Benign Prostatic Hyperplasia
34
Product Used For Unknown Indication
24
Micturition Disorder
19
Drug Use For Unknown Indication
16
Prostatic Adenoma
15
Prostatic Disorder
4
Show More Show More
Anxiety
2
Prostatism
2
Urinary Tract Infection
2
Prostate Cancer
2
Unevaluable Event
2
Multiple Drug Overdose Intentional
2
Dysuria
2
Atrial Fibrillation
1
Ill-defined Disorder
1
Prostatomegaly
1
Suicide Attempt
1
Bronchial Infection
1
Arrhythmia
1
Prostatic Specific Antigen Increase...
1

Permixon Case Reports

What Permixon safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Permixon. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Permixon.